Collaborators
Edith Hessel, Glaxo Smith Kline, Respiratory viral infection of lower airways in COPD, 2018
Ali Ellebedy, Washington University, St Louis, Influenza-specific B cells, 2017
Jean-Francois Toussaint, GlaxoSmithKline, RSV human challenge, 2017
James Harker, Imperial College London, IL-27 in human RSV, 2017
David Nickle, Merck USA, Nasal cell transcriptomics in RSV, 2016
Carolina Lopez, University of Pennsylvania, Defective interfering genomes, 2016
Donald Davidson, Edinburgh University, Antiviral effect of cathelicidin, 2016
Peter Horby, Oxford University, Respiratory viral infection transcriptomics, 2014
Menno de Jong, Amsterdam Medical Centre, Respiratory viral infection transcriptomics, cellular biology, 2014
Chris Woods, Duke University, Experimental human challenge with RSV and influenza transcriptomics, 2013
Miriam Moffatt & Bill Cookson, Imperial College London, Microbiota in RSV infection, 2013
Anne O'Garra, Crick Institute, Whole blood transcriptomics, 2012
Peter Openshaw, Imperial College London, RSV & influenza, 2011
Rafi Ahmed, Emory Vaccine Center, Emory University, Atlanta GA 30322, USA, 2010
Alessandro Sette, La Jolla Institute of Allergy and Immunology, San Diego, California, USA, 2010
Guest Lectures
Imperial Network for Vaccine Research (INVaR): collaborative approaches to tackling global vaccine challenges, London School of Hygiene and Tropical Medicine, Vaccine Centre retreat, Windsor, 2019
Accelerating vaccine development through innovation in experimental medicine, Imperial Forum Workshop, 2019
Human challenge with H3N2 influenza, MRC HIC-Vac, Annual meeting, Liverpool, 2018
Protective immunity in human experimental influenza & RSV infection, London Infections and Immunity Symposium, Crick Institute, 2018
Human influenza challenge studies: cellular immunity in the respiratory tract, Public Health England, HPRU in Respiratory Infections, Colindale, 2018
The role of Controlled Human Infection Models in the licensure of vaccines, World Health Organisation, Product Development for Vaccines Advisory Committee meeting, Geneva, 2018
The challenges of respiratory viral infection, University of Ghent, VIB-UGent Medical Biotechnology Center, 2018
The challenges of respiratory viral infection, Cambridge University, Babraham Institute, 2018
The challenge of RSV vaccination, Imperial College London, Institute of Global Health Innovation Forum, 2018
Protection and pathogenesis in experimental human infections with influenza and RSV, Cardiff University, 2018
Dissecting immunity against RSV using human challenge trials, IABS/WHO 2nd Human Challenge Trials Conference, Rockville MD, 2017
Pathogenesis & protective immunity in experimental human infection with influenza & RSV, Institut Pasteur, Lille, 2017
Influenza H1N1pdm infection of healthy volunteers, European Scientific Working group on Influenza (ESWI), Riga, 2017
Human infection with influenza & RSV: insights from comparative study, EU FP7 PREPARE Annual Meeting, Lisbon, 2017
Pathogenesis & protective immunity in experimental human infection with influenza & RSV, 9. MRC Centre for Inflammation Research, Edinburgh, 2017
Challenging approaches to vaccine development, Pirbright Institute, Woking, 2017
Heterogeneity of RSV-specific cell-mediated immunity in experimentally infected adults, 10th International Respiratory Syncytial Virus Symposium, Bariloche Argentina, 2016
Investigating mucosal immunity in a human challenge model of pandemic H1N1, Heath Protection Research Unit in Respiratory Infections: Annual Symposium, Colindale, 2016
Host susceptibility to other pathogens: Experimental medicine approaches to investigating protective immunity against respiratory viruses, IAID/CDC/Bill & Melinda Gates Foundation: Towards Zero New TB Infections, Rockville MD, 2016
Probing adaptive immunity for vaccine development via human respiratory virus challenge, National Institute for Biological Standards and Control, UK, 2016
Role of airway-surveilling memory CD8+ T cells in mucosal protection against RSV, Biology of Acute Respiratory Tract Infection, Gordon Research Conference, Galveston Texas, 2016
Protective immunity in the human airway against respiratory viral infections., 1st International Meeting on Respiratory Pathogens, International Society for Influenza and other Respiratory Virus Diseases (ISIRV), Singapore, 2015
Controlled human infection studies with RSV and influenza, Lee Kong Chian School of Medicine, Singapore, 2015
Vaccine strategies for protection against respiratory viral diseases., Department of Biotechnology, Nanyang Technology University, Singapore, 2015
Controlled human RSV infection studies: T cell immunity & implications for vaccine development in older people, National Institute of Allergy and Infectious Diseases (NIAID)/Center for Biologics Evaluation and Research (CBER, FDA), Washington DC, 2015
Seasonal influenza vaccines and mutual protection., 3rd ESCMID Conference on Vaccines, Lisbon, 2015
Opportunities for accelerating RSV vaccine development through experimental human infection studies, 23. Oxford Vaccine Group, Oxford, 2015
Human T Cell Responses To RSV Infection In The Lower Airway, 25. 9th International Respiratory Syncytial Virus Symposium, Stellenbosch, 2014
B cell responses following experimental RSV challenge in adult volunteers, RSV Vaccines for the World, Porto, 2013
RSV human challenge studies, Wellcome Trust, 2012
Research Staff
Research Student Supervision
Abraham,P, Cell-mediated immunity in experimental human influenza infection
Avadhan,V, B cell responses to RSV infection of older adults
Gonzalez,L, Quality of antibodies in response to human RSV infection
Guvenal,AK, CD4+ T cell subsets in human respiratory syncytial virus infection
Habibi,M, Correlates of protection after human volunteer infection with RSV
Isola,P, Viral Load as a Correlate of Disease Severity in Human Influenza Infection
Kugathasan,R, Evolution of modern H3N2 influenza A viruses
Lo,V, Risk factors for Severe Respiratory Syncytial Virus (RSV) infection in Children
Nauwelaers,I, Evolutionary viral changes in RSV infection
Patel,M, Inducing B cell immunity to RSV in a phase 1 double blinded placebo controlled clinical trial to a novel intranasal vaccine – SynGEM
Paterson,S, Determinants of Protection and Disease Severity in an Experimental Human Pandemic A(H1N1)2009 Influenza Infection Model
Singh,S, Humoral immunity in experimental human influenza A pH1N1 infection
Ung,S, Humoral responses to human RSV challenge
Zhou,C, Genetic determinants of susceptibility to respiratory viral infection in epithelial cells